Screening and clinical application of molecular markers and targets related to diagnosis and prognosis of retinopathy of prematurity based on multi -omics

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000041070

Enrollment

Unknown

Registered

2020-12-17

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinopathy of prematurity

Interventions

ROP group, non-ROP group and normal control group:Nil

Eligibility

Sex/Gender

All

Age

No minimum to 1 Years

Inclusion criteria

Inclusion criteria: treatment requiring ROP group: (1) GA < 32 weeks, birth weight < 1500g, and in line with the international classification of retinopathy of prematurity (ICROP, 2005) criteria for treatment of ROP, namely: 1) rapid posterior ROP (ap-rop); 2) additional lesions; 3) type I ROP with / without additional lesions; (2) The results showed that the refractive medium was clear and fundus could be followed up; (3) Good compliance and timely follow-up. Non treatment requring ROP group: (1) GA < 32 weeks, birth weight < 1500g, no ROP, or ROP but spontaneous degeneration without treatment; (2) Clear refractive medium, fundus can be routinely checked; (3) Good compliance, can be followed up on time. Normal control group: (1) No existing vitreoretinopathy, need intraocular surgery due to other non-inflammatory factors,such as trauma, congenital cataract, etc.; (2) Good compliance, can be followed up on time.

Exclusion criteria

Exclusion criteria: (1) Infectious diseases such as AIDS, syphilis, hepatitis and cytomegalovirus infection; (2) Major systemic diseases, such as congenital metabolic diseases and blood system diseases; (3) Ocular diseases affecting prognosis and observation, such as congenital cataract, glaucoma, vitreous hemorrhage; (4) Severe systemic malformations; and; Abnormal coagulation function, or taking drugs that may affect metabolic status.

Design outcomes

Primary

Measure	Time frame
treatment requiring ROP;	—

Secondary

Measure	Time frame
fundoscopy;intraocular pressure;plasma/intraocular sample metabolomics;plasma/intraocular sample genomics;plasma/intraocular sample lipomics;plasma/intraocular sample proteomics;plasma/intraocular sample transcriptomics;body weight;	—

Countries

China

Contacts

Public ContactLi Yun

The Second Xiangya Hospital of Central South University

yun.li@csu.edu.cn+86 13637411735

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026